CA2583517C - Preparation incluant de l'acetaminophene, de la cafeine et eventuellement de l'aspirine avec un agent alcalin pour en faciliter l'absorption - Google Patents

Preparation incluant de l'acetaminophene, de la cafeine et eventuellement de l'aspirine avec un agent alcalin pour en faciliter l'absorption Download PDF

Info

Publication number
CA2583517C
CA2583517C CA2583517A CA2583517A CA2583517C CA 2583517 C CA2583517 C CA 2583517C CA 2583517 A CA2583517 A CA 2583517A CA 2583517 A CA2583517 A CA 2583517A CA 2583517 C CA2583517 C CA 2583517C
Authority
CA
Canada
Prior art keywords
analgesic
acetaminophen
antipyretic
composition
caffeine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2583517A
Other languages
English (en)
Other versions
CA2583517A1 (fr
Inventor
Rong Liu
Michael Corbo
Jatin Desai
Gerard P. Frunzi
Xiaohong Qi
Candice Y. Choi
Rahul R. Gandhi
Atef Z. Boulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA2583517A1 publication Critical patent/CA2583517A1/fr
Application granted granted Critical
Publication of CA2583517C publication Critical patent/CA2583517C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2583517A 2004-10-28 2005-10-26 Preparation incluant de l'acetaminophene, de la cafeine et eventuellement de l'aspirine avec un agent alcalin pour en faciliter l'absorption Expired - Fee Related CA2583517C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62281204P 2004-10-28 2004-10-28
US60/622,812 2004-10-28
PCT/US2005/038507 WO2006049978A1 (fr) 2004-10-28 2005-10-26 Préparation incluant de l’acétaminophène, de la caféine et éventuellement de l’aspirine avec un agent alcalin pour en faciliter l’absorption

Publications (2)

Publication Number Publication Date
CA2583517A1 CA2583517A1 (fr) 2006-05-11
CA2583517C true CA2583517C (fr) 2013-06-04

Family

ID=35744599

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2583517A Expired - Fee Related CA2583517C (fr) 2004-10-28 2005-10-26 Preparation incluant de l'acetaminophene, de la cafeine et eventuellement de l'aspirine avec un agent alcalin pour en faciliter l'absorption

Country Status (17)

Country Link
US (1) US20070298096A1 (fr)
EP (1) EP1807068B1 (fr)
JP (1) JP2008518914A (fr)
CN (1) CN101048155A (fr)
AR (1) AR051145A1 (fr)
AT (1) ATE460930T1 (fr)
AU (1) AU2005302618B2 (fr)
BR (1) BRPI0520000A2 (fr)
CA (1) CA2583517C (fr)
DE (1) DE602005020048D1 (fr)
MX (1) MX2007005121A (fr)
NO (1) NO20072255L (fr)
PE (1) PE20061125A1 (fr)
PL (1) PL1807068T3 (fr)
PT (1) PT1807068E (fr)
RU (1) RU2398571C2 (fr)
WO (1) WO2006049978A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0607085D0 (en) * 2006-04-07 2006-05-17 Smithkline Beecham Corp Novel compositions
CN100417385C (zh) * 2006-09-26 2008-09-10 林星 一种用于治疗外伤的外用制剂
GB0707489D0 (en) * 2007-04-18 2007-05-23 Renaissance Pharma Compounds
CN101596163B (zh) * 2008-06-06 2012-06-27 康美保宁（四川）制药有限公司 阿咖酚微丸制剂及其制备方法
GB0813929D0 (en) * 2008-07-30 2008-09-03 Glaxo Group Ltd Novel method
CN102861040B (zh) * 2012-08-02 2014-04-23 广东环球制药有限公司 含有阿司匹林、对乙酰氨基酚和咖啡因的药物组合物及其制备方法
CN102949401A (zh) * 2012-09-06 2013-03-06 广东九明制药有限公司 对乙酰氨基酚、乙酰水杨酸和咖啡因组合物及其制备工艺
US10124005B1 (en) * 2017-12-15 2018-11-13 Lisa Josette Myslinski Multisymptom migraine combination medication
CN110711197B (zh) * 2018-07-12 2023-11-24 北京恒润泰生医药科技有限公司 阿司匹林和对乙酰氨基酚的分子复合物加咖啡因,其制备,活性及应用
CN108853124A (zh) * 2018-08-15 2018-11-23 康美保宁（四川）制药有限公司 一种阿咖酚制剂及其制剂方法
GB202007670D0 (en) * 2020-05-22 2020-07-08 Glaxosmithkline Consumer Healthcare Holdings Us Llc Pharmaceutical composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4294819A (en) * 1980-08-18 1981-10-13 Bristol-Myers Company Alkaline analgesic capsule
CA1182049A (fr) * 1981-07-13 1985-02-05 Francis J. Sterbenz Compose d'apap et d'antiacide
US5296241A (en) * 1991-04-03 1994-03-22 Brimberg Barnett J Therapeutic composition and method of using same for treatment of hangover
JP3122748B2 (ja) * 1991-11-29 2001-01-09 ライオン株式会社 イブプロフェン含有解熱鎮痛剤
JP3172749B2 (ja) * 1992-02-17 2001-06-04 ライオン株式会社 イブプロフェン含有製剤
JPH06227995A (ja) * 1993-02-03 1994-08-16 Takeda Chem Ind Ltd 安定化された固型製剤
JPH07206689A (ja) * 1994-01-21 1995-08-08 Barnett Lab Ltd 治療組成物および宿酔の治療のためのこの組成物の使用法
DE19502789A1 (de) * 1995-01-28 1996-08-01 Dirk Krischenowski Arzneimittel
GB9704524D0 (en) * 1997-03-05 1997-04-23 Smithkline Beecham Plc Composition
US5972916A (en) * 1997-07-14 1999-10-26 Bristol-Myers Squibb Company Compositions containing the nonprescription combination of acetaminophen, aspirin and caffeine to alleviate the pain and symptoms of migraine
JP2002012557A (ja) * 2000-06-28 2002-01-15 Lion Corp 内服薬組成物
JP4365107B2 (ja) * 2001-05-25 2009-11-18 エスエス製薬株式会社 医薬組成物
JP4553552B2 (ja) * 2003-01-08 2010-09-29 日東薬品工業株式会社 生体リズム応用キット

Also Published As

Publication number Publication date
PE20061125A1 (es) 2006-11-08
PL1807068T3 (pl) 2010-08-31
AU2005302618A1 (en) 2006-05-11
BRPI0520000A2 (pt) 2009-04-07
AR051145A1 (es) 2006-12-20
NO20072255L (no) 2007-07-18
JP2008518914A (ja) 2008-06-05
PT1807068E (pt) 2010-04-19
CN101048155A (zh) 2007-10-03
RU2398571C2 (ru) 2010-09-10
EP1807068A1 (fr) 2007-07-18
MX2007005121A (es) 2007-06-22
EP1807068B1 (fr) 2010-03-17
WO2006049978A1 (fr) 2006-05-11
ATE460930T1 (de) 2010-04-15
CA2583517A1 (fr) 2006-05-11
AU2005302618B2 (en) 2009-10-22
DE602005020048D1 (de) 2010-04-29
RU2007119641A (ru) 2008-12-10
US20070298096A1 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
CA2583517C (fr) Preparation incluant de l'acetaminophene, de la cafeine et eventuellement de l'aspirine avec un agent alcalin pour en faciliter l'absorption
US5200193A (en) Pharmaceutical sustained release matrix and process
AU2002300238B2 (en) Process for manufacturing bite-dispersion tablets
AU684522B2 (en) Pharmaceutical thermal infusion process
EP1363608B1 (fr) Compositions contenant de l'ibuprofene et du diphenhydramine et leur utilisation pour le traitement des troubles du sommeil
US7741374B1 (en) Methods of use of fenofibric acid
WO1988008299A1 (fr) Matrice et processus de liberation prolongee de substances pharmaceutiques
CN101257894A (zh) 高水溶性药物的缓释药物组合物
JP2009528329A (ja) 事故的誤用および不法転用を防止するための耐破砕性錠剤
US20130039981A1 (en) Quick Dissolving, Long Acting Zinc Therapeutic Formulations
Higton The pharmaceutics of ibuprofen
WO1995022974A2 (fr) Comprimes enrobes de paracetamol et de domperidone
WO2014104929A1 (fr) Composition pharmaceutique pour traiter une infection par le vih
US7993673B2 (en) Swallow tablet comprising paracetamol
WO1996031218A1 (fr) Composition pharmaceutique contenant du sucralfate
AU2002317772A1 (en) Swallow tablet comprising paracetamol
CN105407876B (zh) 抗结核病的稳定的包含异烟肼颗粒和利福喷汀颗粒的可分散的片剂及其制备方法
JPH08333259A (ja) スクラルファート含有製剤組成物
ZA200504425B (en) Pharmaceutical formulations comprins beta-2 andrenoreceptor antagonists and xanthines
Shyamaladevi et al. Formulation and evaluation of bilayer tablets of Montelukast sodium immediate release and Doxofylline sustained release
CZ20002258A3 (cs) Způsob přípravy stiskem disperzních tablet

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20181026